NEW AND NOW APPROVED
For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC
COMBINED POWER TO CHANGE THE GAME IN EGFR+ mNSCLC1
RYBREVANT® + LAZCLUZE™ form the first and only multitargeted combination to show statistically significant mPFS improvement vs osimertinib1,2
23.7 months (95% CI: 19.1, 27.7) vs 16.6 months (95% CI: 14.8, 18.5) for osimertinib; (HR=0.70 [95% CI: 0.58, 0.85]; P=0.0002)
Clinical experience in first line
Efficacy and safety profile of RYBREVANT® + LAZCLUZE™
See the results
Resources for you and your practice
Support your patients throughout their treatment journey
Learn moreCI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; mNSCLC, metastatic non–small cell lung cancer; MOA, mechanism of action; mPFS, median progression-free survival; NSCLC, non–small cell lung cancer; PFS, progression-free survival.
References:
- RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. Press release. Johnson & Johnson. August 20, 2024. Accessed August 20, 2024.
https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-us-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer-302226047.html
